* InspireMD Inc NSPR.OQ NSPR.O is expected to show a
rise in
quarterly revenue when it reports results on November 8.
* The Tel Aviv-yafo Israel-based company is expected to
report
a 30.7% increase in revenue to $1.4 million from $1.07 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data.
* Refinitiv's mean analyst estimate for InspireMD Inc is
for a
loss of 73 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for InspireMD
Inc is
$5.6, above its last closing price of $1.11.
This summary was machine generated November 4 at 14:31 GMT. All
figures in US dollars unless otherwise stated